Revelation Biosciences, Inc. · NASDAQ:REVB
Revelation Biosciences — Investor Presentation (February 2022)
12 slides from Revelation Biosciences's investor presentation, Feb 11, 2022
Slide 1: Developing innovative therapeutics and diagnostics to address unmet needs
Developing innovative therapeutics and diagnostics to address unmet needs Corporate Presentation / February 2022 www.revbiosciences.com
Slide 2: Forward-Looking Statements
Forward - Looking Statements This presentation contains forward - looking statements as defined in the Private Securities Litigation Reform Act of 1995 , as amended . Forward - looking statements are statements that are not historical facts . These forward - looking statements are generally identifi
Slide 3: Development Pipeline
Development Pipeline 3 Revelation is developing therapeutic and diagnostics base on modulation or measurement of the innate immune response Therapeutic Pipeline Discovery Preclinical Phase 1 Phase 2 Phase 3 Approval REVTx - 99a REVTx - 99b REVTx - 200 Diagnostic Pipeline Research Development Clinica
Slide 4: Project Milestones
Project Milestones Project Milestone Estimated Timing REVTx - 99a: Intranasal solution for the prevention and/or treatment of respiratory viral infection • Preclinical data (in vitro) for SARS - CoV - 2 and variants x Q1 2022 • Preclinical data (in vivo) for SARS - CoV - 2 and variants Q2 2022 • Pha
Slide 5: Protective Cytokines: How Our Therapeutic Candidates Work
Protective Cytokines How Our Therapeutic Candidates Work • The active ingredient in our product candidates is Phosphorylated Hexa - Acyl Disaccharide ( PHAD) • We have developed propriety formulations to deliver the active ingredient to the local intran asal cavity • PHAD activates the local innate
Slide 6: Clinical Data Supports Our Proposed Mechanism of Action
Clinical Data Supports Our Proposed Mechanism of Action Safety x All doses of REVTx - 99 were well tolerated with no significant or serious adverse events x Drug related adverse events were all mild and limited to the local nasal mucosa and included runny nose or mild nasal congestion at the higher
Slide 7: REVTx-99a Program Highlights
REVTx - 99a Program Highlights • REVTx - 99a has the potential to work broadly vs multiple virus types including influenza and SARS - COV - 2 • Based on a solid scientific foundation backed up by nonclinical and clinical data • IP covering formulations and methods of use filed • Multiple potentially
Slide 8: REVTx-99b Program Highlights
REVTx - 99b Program Highlights • New nonsteroidal therapies for allergies are urgently needed • Development rationale based on a solid scientific foundation • Eotaxin, an inflammatory cytokine, propagates allergies and inflammation through binding to the CCR3 receptor, which is expressed on a range
Slide 9: REVTx-200 Program Highlights
REVTx - 200 Program Highlights 9 x REVTx - 200 has the potential to be used with most respiratory viral vaccines currently in use or being developed » Identify and work with multiple partners with existing vaccines to evaluate REVTx - 200 nonclinically in 1H 2022 » Strong scientific advisory board f
Slide 10: REVDx-501: Rapid Test Kit for Viral Infection
REVDx - 501: Rapid Test Kit for Viral Infection • REVDx - 501 (REVID Œ ) is a diagnostic device in development for the detection of respiratory viral infection (SARS - CoV - 2, influenza A and B, parainfluenza, etc.) • REVDx - 501 detects IP - 10, a key cytokine that is upregulated in nasal and oral
Slide 11: Cap Table and Financial Overview
11 Beneficial holders Percent George Tidmarsh, M.D., Ph.D. 13.5% All other management 11.0% Total management 24.5% AXA IM Prime Impact Fund 13.8% Petra Investment Holdings, LLC 12.4% Armistice Capital 9.1% LifeSci Venture Partners II, LP & Affiliates 7.3% Monashee Investments 6.4% Cap Table Shares C
Slide 12: Thank you!
For more information please visit www.revbiosciences.com Thank you!
Revelation Biosciences — Investor Presentation (February 2022) on 6ix